Zydus Cadila Healthcare has received the final approval from the United States Food & Drug Administration (USFDA) to market Fluocinonide cream USP, 0.1%.
As per the company's press release, the drug is used for the treatment of variety of skin conditions (like psoriasis, eczema, dermatitis, allergies and rash). The medicine would be manufactured at its topical manufacturing unit at Ahmedabad, Gujarat.
With an additional feather in Cadila Heathcare's cap, the Group now has a total of 279 approvals and has filed over 386 ANDAs (Abbreviated New Drug Applications) since the commencement of the filing process in FY 2003-04.
The announcement was released after market hours yesterday, 11 February 2020.
Shares of Cadila Healthcare fell 1.51% to close at Rs 274.60 on BSE on Tuesday, 11 February 2020.
Cadila Healthcare is a pharmaceutical company based out of India. It is a global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 25,000 people worldwide and aspires to be a research-based pharmaceutical company by 2020.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)